Abstract
We sincerely appreciate the thoughtful comments from Drs. Ginsberg and Rosner regarding our recent article on the efficacy of tumor necrosis factor (TNF) inhibitors for refractory leg ulcers in cutaneous polyarteritis nodosa (PAN).1 We are pleased to learn that their previously published experience with infliximab therapy in refractory systemic PAN yielded results consistent with our observations in patients with cutaneous-limited disease.2
